Pharma Two B to Present Additional Positi... - Cure Parkinson's

Cure Parkinson's

26,039 members27,333 posts

Pharma Two B to Present Additional Positive Results from P2B001 Phase 3 Trial at 2023 American Academy of Neurology Annual Meeting

Farooqji profile image
0 Replies

Results showed P2B001, a once-daily fixed-dose combination of low dose pramipexole and low dose rasagiline, showed comparable efficacy to marketed optimally titrated pramipexole, with significantly reduced sleep-related and dopaminergic side effectsData analysis also confirmed patients treated with P2B001 developed significantly less new-onset excessive daytime sleepiness when compared to marketed pramipexole

globenewswire.com/news-rele...

Written by
Farooqji profile image
Farooqji
To view profiles and participate in discussions please or .
Read more about...

Not what you're looking for?

You may also like...

Benfotiamine In The Mix For PD Again?

< 0.001) when compared with the BFT per se; (p < 0.001) when compared with the low dose of BFT; (p...

Anyone else trying ibogaine?

I started a low dose regime of ibogaine a few days ago and the results are remarkable in just a few...

Parkinson’s and vagal nerve stimulation, promising human studies.

RESULTS: PD patients showed instable gait with insufficient range of motion during usual walking....

Finding the Right Dose of Levodopa

to C/L, I am taking ¼ pramipexole 0.25 in the morning plus another ½ pramipexole at night. Any...

Another Potential Benefit Of Melatonin for PwP

of cataract compared with the general older population, which if left untreated can result in poor...